AbbVie
ABBV
#26
Rank
โ‚ฌ343.19 B
Marketcap
194,18ย โ‚ฌ
Share price
-1.15%
Change (1 day)
19.88%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

Revenue for AbbVie (ABBV)

Revenue in 2025 (TTM): โ‚ฌ53.37 Billion

According to AbbVie's latest financial reports the company's current revenue (TTM ) is โ‚ฌ51.22 Billion. In 2024 the company made a revenue of โ‚ฌ54.13 Billion an increase over the revenue in the year 2023 that were of โ‚ฌ49.13 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for AbbVie from 2011 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚ฌ53.37 B-1.41%
2024 โ‚ฌ54.13 B10.17%
2023 โ‚ฌ49.13 B-9.21%
2022 โ‚ฌ54.12 B9.07%
2021 โ‚ฌ49.62 B33.25%
2020 โ‚ฌ37.23 B25.4%
2019 โ‚ฌ29.69 B3.72%
2018 โ‚ฌ28.63 B21.75%
2017 โ‚ฌ23.51 B-3.52%
2016 โ‚ฌ24.37 B16.59%
2015 โ‚ฌ20.90 B27.39%
2014 โ‚ฌ16.41 B20.62%
2013 โ‚ฌ13.60 B-2.08%
2012 โ‚ฌ13.89 B3.44%
2011 โ‚ฌ13.43 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Pfizer
PFE
โ‚ฌ53.92 B 5.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ41.25 B-19.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
โ‚ฌ51.03 B-0.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚ฌ30.89 B-39.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
โ‚ฌ24.98 B-51.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
โ‚ฌ8.64 B-83.12%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
โ‚ฌ36.37 B-28.99%๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
โ‚ฌ49.92 B-2.54%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
โ‚ฌ2.30 B-95.50%๐Ÿ‡บ๐Ÿ‡ธ USA